Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | CFO | July 07, 2026 | July 09, 2026 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | CHIEF FINANCIAL OFFICER | June 02, 2022 | June 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.29 · Expires 2036-07-06 | Direct | 48,285 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 48,285 · Balance 48,285 F1: The option grant described in this Form 4 filing vests as to 25% of the original shares on July 7, 2027 and as to an additional 6.25% of the original shares each successive quarter and until July 7, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant described in this Form 4 filing vests as to 25% of the original shares on July 7, 2027 and as to an additional 6.25% of the original shares each successive quarter and until July 7, 2030.
GENOCEA BIOSCIENCES, INC.
Report date June 02, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,388 |
Reported balance
After 2022-06-02 transaction · row 1
1 source rowRow 1 · 2022-06-02 · Sale · Disposed 1,355 · Balance 75,388 F1: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Bioverativ Inc.
Report date March 08, 2018 · Filed March 08, 2018
Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 1
1 source rowRow 1 · 2018-03-08 · Disposition to issuer · Disposed 2,791 · Balance 0 F1: Includes shares subject to restricted stock units. See also note 4. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-08 · Disposition to issuer · Disposed 2,780 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-08 · Disposition to issuer · Disposed 7,273 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $52.08 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-08 · Disposition to issuer · Disposed 7,030 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-08 · Disposition to issuer · Disposed 11,062 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares subject to restricted stock units. See also note 4.
F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.
F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 20:11 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 48,285 | $5.29 Strike: $5.29 | $255,427.65 |
DisclosureSEC source: 0001108205-26-000091 · wk-form4_1783627863.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,285 Underlying: Common Stock · 48,285 shares Expires 2036-07-06 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on July 7, 2027 and as to an additional 6.25% of the original shares each successive quarter and until July 7, 2030. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 20:03 UTC | CURIS INC CRIS · Entity 8401 | ConversionSeries B Convertible Preferred Stock · Derivative | 50 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001108205-26-000038 · wk-form4_1774296203.xml · derivative · entry 2 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.exercise_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.expiration_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. Read SEC document |
| March 20, 2026 Filed Mar 23, 2026 20:03 UTC | CURIS INC CRIS · Entity 8401 | ConversionCommon Stock | 66,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001108205-26-000038 · wk-form4_1774296203.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:21 UTC | CURIS INC CRIS · Entity 8401 | GrantSeries C Warrant (right to buy) · Derivative | 66,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001108205-26-000026 · wk-form4_1773865293.xml · derivative · entry 4 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,666 shares Expires 2027-07-08 F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F5 · derivative.exercise_date: The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:21 UTC | CURIS INC CRIS · Entity 8401 | GrantSeries B Warrant (right to buy) · Derivative | 66,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001108205-26-000026 · wk-form4_1773865293.xml · derivative · entry 3 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,666 shares Expires not disclosed F4 · derivative.exercise_price: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days. F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F4 · derivative.exercise_date: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days. F4 · derivative.expiration_date: The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:21 UTC | CURIS INC CRIS · Entity 8401 | GrantSeries A Warrant (right to buy) · Derivative | 66,666 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001108205-26-000026 · wk-form4_1773865293.xml · derivative · entry 2 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,666 shares Expires 2031-01-08 F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F3 · derivative.exercise_date: Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 20:21 UTC | CURIS INC CRIS · Entity 8401 | GrantSeries B Convertible Preferred Stock · Derivative | 50 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001108205-26-000026 · wk-form4_1773865293.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50 Underlying: Common Stock · 66,666 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). F2 · price: Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person. F1 · derivative.exercise_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). F1 · derivative.expiration_date: Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:13 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 135,000 | $3.13 Strike: $3.13 | $422,550.00 |
DisclosureSEC source: 0001108205-25-000065 · wk-form4_1747944773.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2035-01-27 F1 · date: This option grant, as disclosed in Curis Inc.'s 2025 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 28, 2025, contingent upon shareholder approval of Curis's Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if Amendment No. 1 to the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 20, 2025, at the 2025 annual meeting of shareholders, Curis's shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Plan. F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:11 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 15,000 | $3.13 Strike: $3.13 | $46,950.00 |
DisclosureSEC source: 0001108205-25-000018 · wk-form4_1738271478.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-01-27 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:12 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 39,000 | $11.62 Strike: $11.62 | $453,180.00 |
DisclosureSEC source: 0001108205-24-000055 · wk-form4_1716495126.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2034-01-18 F1 · date: This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 19, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to, among other things, increase the number of shares authorized for issuance thereunder and increase the per participant limit on the number of shares subject to awards that can be granted annually to participants in the plan; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan. F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 19, 2025 and as to an additional 6.25% of the original shares each successive quarter and until January 19, 2028. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:10 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001108205-23-000011 · wf-form4_167459462169459.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-01-19 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 20, 2024 and as to an additional 6.25% of the original shares each successive quarter and until January 20, 2027. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 16:13 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 1,355 | $0.06 | $81.30 |
DisclosureSEC source: 0001457612-22-000075 · wf-form4_165428718048421.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,388 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| May 26, 2022 Filed May 26, 2022 16:11 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 24,407 | $0.08 | $1,867.14 |
DisclosureSEC source: 0001457612-22-000060 · wf-form4_165359588823596.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,743 F1 · balance_after: Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.0765 to $0.0766, inclusive. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 08:17 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 963 | $1.25 | $1,203.75 |
DisclosureSEC source: 0001457612-22-000045 · wf-form4_164916106048565.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 16:11 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 2,873 | $1.10 | $3,160.30 |
DisclosureSEC source: 0001457612-22-000030 · wf-form4_164754782084656.xml · nonDerivative · entry 2 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,738 F2 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 16:11 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001457612-22-000030 · wf-form4_164754782084656.xml · derivative · entry 3 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2032-03-15 F3 · derivative.exercise_date: The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 16:11 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-22-000030 · wf-form4_164754782084656.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,611 F1 · shares: Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date. Read SEC document |
| June 01, 2021 Filed Mar 16, 2022 17:31 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 511 | $2.23 | $1,139.53 |
DisclosureSEC source: 0001457612-22-000020 · wf-form5_164746625165852.xml · nonDerivative · entry 2 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,486 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 02, 2021 Filed Mar 16, 2022 17:31 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 925 | $2.71 | $2,506.75 |
DisclosureSEC source: 0001457612-22-000020 · wf-form5_164746625165852.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,997 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:59 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-21-000042 · wf-form4_161600393732739.xml · derivative · entry 3 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_date: Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The"target" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance. F4 · derivative.expiration_date: Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The"target" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:59 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001457612-21-000042 · wf-form4_161600393732739.xml · derivative · entry 2 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-03-15 F2 · derivative.exercise_date: The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:59 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-21-000042 · wf-form4_161600393732739.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · shares: Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 16:19 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 24,938 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001457612-20-000079 · wf-form4_159112913161265.xml · derivative · entry 2 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,938 Underlying: Common Stock · 24,938 shares Expires 2030-06-01 F2 · derivative.exercise_date: The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 16:19 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 6,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-20-000079 · wf-form4_159112913161265.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,623 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Amended and Restated 2014 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest one-fourth (1/4) on each of the first four (4) anniversaries on the date of grant. Read SEC document |
| April 02, 2020 Filed Apr 6, 2020 16:06 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 46,313 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001457612-20-000025 · wf-form4_158620355845940.xml · derivative · entry 2 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,313 Underlying: Common Stock · 46,313 shares Expires 2030-04-02 F2 · derivative.exercise_date: The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| April 02, 2020 Filed Apr 6, 2020 16:06 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 12,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-20-000025 · wf-form4_158620355845940.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,299 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Amended and Restated 2014 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest one-fourth (1/4) on each of the first four (4) anniversaries on the date of grant. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 15:10 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 475,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001457612-19-000034 · wf-form4_155198943936581.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: The Stock Option shall become exercisable as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of the Grant Date (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest) Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:22 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerNon-Qualified Stock Option · Derivative | 11,062 | Not disclosed Strike: $44.51 | Not disclosed |
DisclosureSEC source: 0001127602-18-010658 · form4.xml · derivative · entry 5 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,062 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:22 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerNon-Qualified Stock Option · Derivative | 7,030 | Not disclosed Strike: $52.08 | Not disclosed |
DisclosureSEC source: 0001127602-18-010658 · form4.xml · derivative · entry 4 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,030 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:22 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerRestricted Stock Units · Derivative | 7,273 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010658 · form4.xml · derivative · entry 3 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,273 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:22 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerRestricted Stock Units · Derivative | 2,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010658 · form4.xml · derivative · entry 2 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,780 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 12:22 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerCommon Stock | 2,791 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-010658 · form4.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes shares subject to restricted stock units. See also note 4. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 17:02 UTC | Bioverativ Inc. BIVV · Entity 168487 | Tax withholdingCommon Stock | 105 | $104.73 | $10,996.65 |
DisclosureSEC source: 0001127602-18-010132 · form4.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,791 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 17:13 UTC | Bioverativ Inc. BIVV · Entity 168487 | Tax withholdingCommon Stock | 168 | $104.30 | $17,522.40 |
DisclosureSEC source: 0001127602-18-008447 · form4.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,896 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 17:11 UTC | Bioverativ Inc. BIVV · Entity 168487 | Exercise / conversionRestricted Stock Units · Derivative | 1,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006428 · form4.xml · derivative · entry 3 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,780 Underlying: Common Stock · 1,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 17:11 UTC | Bioverativ Inc. BIVV · Entity 168487 | Tax withholdingCommon Stock | 454 | $103.52 | $46,998.08 |
DisclosureSEC source: 0001127602-18-006428 · form4.xml · nonDerivative · entry 2 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,064 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 17:11 UTC | Bioverativ Inc. BIVV · Entity 168487 | Exercise / conversionCommon Stock | 1,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006428 · form4.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 17:18 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantRestricted Stock Units · Derivative | 7,273 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-003819 · form4.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,273 Underlying: Common Stock · 7,273 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019. F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019. Read SEC document |
| June 28, 2017 Filed Jun 29, 2017 17:10 UTC | Bioverativ Inc. BIVV · Entity 168487 | SaleCommon Stock | 818 | $60.47 | $49,464.46 |
DisclosureSEC source: 0001127602-17-022382 · form4.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,128 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| May 02, 2017 Filed May 3, 2017 16:27 UTC | Bioverativ Inc. BIVV · Entity 168487 | Tax withholdingCommon Stock | 99 | $57.48 | $5,690.52 |
DisclosureSEC source: 0001127602-17-016620 · form4.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,946 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document |
| March 02, 2017 Filed Mar 3, 2017 16:15 UTC | Bioverativ Inc. BIVV · Entity 168487 | Tax withholdingCommon Stock | 113 | $52.81 | $5,967.53 |
DisclosureSEC source: 0001127602-17-010129 · form4.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,045 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:10 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 7,030 | $0.00 Strike: $52.08 | $0.00 |
DisclosureSEC source: 0001127602-17-009677 · form4.xml · derivative · entry 3 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,030 Underlying: Common Stock · 7,030 shares Expires 2027-02-28 F4 · derivative.exercise_date: This option vests in full on the third anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:10 UTC | Bioverativ Inc. BIVV · Entity 168487 | Tax withholdingCommon Stock | 211 | $47.76 | $10,077.36 |
DisclosureSEC source: 0001127602-17-009677 · form4.xml · nonDerivative · entry 2 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 16:10 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantCommon Stock | 3,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009677 · form4.xml · nonDerivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,369 F1 · shares: Includes restricted stock units granted by Bioverativ Inc. ("Bioverativ") to the reporting person as a result of the conversion of existing Biogen Inc. ("Biogen") restricted stock units held by the reporting person prior to the spin-off of Bioverativ from Biogen on February 1, 2017 ("Spin-Off"), as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off. Restricted stock units that are unvested continue to vest on the dates of the original Biogen awards. F2 · balance_after: Includes 9 shares acquired in a pro rata distribution by Biogen in connection with the Spin-Off. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 16:42 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 11,043 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-006625 · form4.xml · derivative · entry 2 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,043 Underlying: Common Stock · 11,043 shares Expires 2027-02-14 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 16:42 UTC | Bioverativ Inc. BIVV · Entity 168487 | GrantRestricted Stock Units · Derivative | 4,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-006625 · form4.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,170 Underlying: Common Stock · 4,170 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. Read SEC document |
| February 14, 2017 Filed Mar 27, 2017 16:33 UTC Amendment | Bioverativ Inc. BIVV · Entity 168487 | GrantNon-Qualified Stock Option · Derivative | 11,062 | $0.00 Strike: $44.51 | $0.00 |
DisclosureSEC source: 0001127602-17-012958 · form4a.xml · derivative · entry 1 Duvall Diantha · CIK 0001696784 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,062 Underlying: Common Stock · 11,062 shares Expires 2027-02-14 F1 · shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F2 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. F1 · derivative.underlying_shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F1 · balance_after: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.